drugset / Trial / NCT01138735

Epiduo Pediatric Acne Study

NCT01138735

Phase 4 Completed 285 enrolled Galderma R&D
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.

Timeline

Start
2010-06
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adapalene Other / unclassified 0.1 % Topical
Comparator Benzoyl Peroxide Other / unclassified 2.5 % Topical

Indications